FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Conway Robert G 2. Issuer Name and Ticker or Trading Symbol AGILE THERAPEUTICS INC [ AGRX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP Chief Supply Chain Officer
(Last)         (First)         (Middle)
101 POOR FARM ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)
11/19/2020
(Street)
PRINCETON, NJ 08540
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  11/19/2020    M    4149  A $1.76  22896 (1) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)  $1.76  11/19/2020    M        4149    (2) 12/8/2020  Common Stock  4149  $0  0  D   

Explanation of Responses:
(1)  The total number of shares reported in Column 5 includes 6,200 shares that were inadvertently omitted from the Reporting Person's original Form 3 and subsequent Forms 4. The original Form 3 has been amended to reflect this correction.
(2)  The option was granted on December 9, 2010 and is currently fully vested and exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Conway Robert G
101 POOR FARM ROAD
PRINCETON, NJ 08540


SVP Chief Supply Chain Officer

Signatures
/s/ Robert G. Conway 11/23/2020
**Signature of Reporting Person Date
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Dec 2020 to Jan 2021 Click Here for more Agile Therapeutics Charts.
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Jan 2020 to Jan 2021 Click Here for more Agile Therapeutics Charts.